Thalidomide Inhibits Tumor Necrosis Factor-α Production and Antigen Presentation by Langerhans Cells
- 1 November 2003
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 121 (5) , 1060-1065
- https://doi.org/10.1046/j.1523-1747.2003.12565.x
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential usesJournal of the American Academy of Dermatology, 1996
- Cytokine‐dependent regulation of growth and maturation in murine epidermal dendritic cell linesEuropean Journal of Immunology, 1995
- Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunology Today, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992
- Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytesJournal of the American Academy of Dermatology, 1984
- Role of antigen-presenting cells in the development and persistence of contact hypersensitivity.The Journal of Experimental Medicine, 1980